A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review
BackgroundDe novo neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) and few markers are available for screening and monitoring. Potential circulating or fluid markers might facilitate early diagnosis thus improving prognosis of NEPC, especially for de novo NEPC.Case pr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1508410/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589897309880320 |
|---|---|
| author | Weizhe Han Nihati Rexiati Fang Yu Yongzhi Wang Yueli Tian Jianyuan Wu Gang Wang Tao Liu Zhonghua Yang |
| author_facet | Weizhe Han Nihati Rexiati Fang Yu Yongzhi Wang Yueli Tian Jianyuan Wu Gang Wang Tao Liu Zhonghua Yang |
| author_sort | Weizhe Han |
| collection | DOAJ |
| description | BackgroundDe novo neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) and few markers are available for screening and monitoring. Potential circulating or fluid markers might facilitate early diagnosis thus improving prognosis of NEPC, especially for de novo NEPC.Case presentationA man of 71-year was presented with elevated level of serum carcinoembryonic antigen (CEA) (1296.5 ng/ml) and normal PSA (0.47ng/ml). Gastrointestinal endoscopy showed no signs of gastric or colorectal cancer. Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) and prostate-specific membrane antigen PET-CT (PSMA PET-CT) indicated prostate cancer with metastases including pelvic lymph nodes, bone as well as lung metastases. Biopsy of prostate revealed mixed carcinoma including small cell neuroendocrine carcinoma (SCNEC) and adenocarcinoma (Gleason score of 4 + 5). Immunohistochemistry (IHC) staining and next generation sequencing demonstrated a strong expression of chromogranin A (CgA), synaptophysin (SYN) and CEA, and a germline mutation in BRCA2, respectively. After a prostatic massage, an increased level of CEA (137 ng/ml vs 5 ng/ml) was detected in urine. Olaparib, a Poly ADP-ribose polymerase inhibitor (PARPi), combined with androgen deprivation therapy (ADT) were administrated. FDG PET-CT indicated tumor regression in both quantity and size three months later, and CEA levels of serum and urine decreased to 23 ng/ml and 2.4 ng/ml 4 months later, respectively.ConclusionThis is the first report of a de novo NEPC presented with an elevated level of CEA, in which CEA was also detected in urine specimen post a prostatic massage. After a combination treatment of ADT for 3 months, levels of CEA in both serum and urine decreased sharply when tumor regressed radiologically. CEA might be a marker of screening and monitoring of NEPC. |
| format | Article |
| id | doaj-art-3808a4f93f3745c0a065cff1d3833064 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-3808a4f93f3745c0a065cff1d38330642025-01-24T05:21:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15084101508410A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature reviewWeizhe Han0Nihati Rexiati1Fang Yu2Yongzhi Wang3Yueli Tian4Jianyuan Wu5Gang Wang6Tao Liu7Zhonghua Yang8Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, ChinaClinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Biological Repositories, Human Genetic Resource Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, ChinaBackgroundDe novo neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) and few markers are available for screening and monitoring. Potential circulating or fluid markers might facilitate early diagnosis thus improving prognosis of NEPC, especially for de novo NEPC.Case presentationA man of 71-year was presented with elevated level of serum carcinoembryonic antigen (CEA) (1296.5 ng/ml) and normal PSA (0.47ng/ml). Gastrointestinal endoscopy showed no signs of gastric or colorectal cancer. Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) and prostate-specific membrane antigen PET-CT (PSMA PET-CT) indicated prostate cancer with metastases including pelvic lymph nodes, bone as well as lung metastases. Biopsy of prostate revealed mixed carcinoma including small cell neuroendocrine carcinoma (SCNEC) and adenocarcinoma (Gleason score of 4 + 5). Immunohistochemistry (IHC) staining and next generation sequencing demonstrated a strong expression of chromogranin A (CgA), synaptophysin (SYN) and CEA, and a germline mutation in BRCA2, respectively. After a prostatic massage, an increased level of CEA (137 ng/ml vs 5 ng/ml) was detected in urine. Olaparib, a Poly ADP-ribose polymerase inhibitor (PARPi), combined with androgen deprivation therapy (ADT) were administrated. FDG PET-CT indicated tumor regression in both quantity and size three months later, and CEA levels of serum and urine decreased to 23 ng/ml and 2.4 ng/ml 4 months later, respectively.ConclusionThis is the first report of a de novo NEPC presented with an elevated level of CEA, in which CEA was also detected in urine specimen post a prostatic massage. After a combination treatment of ADT for 3 months, levels of CEA in both serum and urine decreased sharply when tumor regressed radiologically. CEA might be a marker of screening and monitoring of NEPC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1508410/fullneuroendocrine prostate cancer (NEPC)carcinoembryonic antigen (CEA)homologous recombination repair (HRR)markerprostate cancer |
| spellingShingle | Weizhe Han Nihati Rexiati Fang Yu Yongzhi Wang Yueli Tian Jianyuan Wu Gang Wang Tao Liu Zhonghua Yang A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review Frontiers in Oncology neuroendocrine prostate cancer (NEPC) carcinoembryonic antigen (CEA) homologous recombination repair (HRR) marker prostate cancer |
| title | A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review |
| title_full | A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review |
| title_fullStr | A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review |
| title_full_unstemmed | A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review |
| title_short | A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review |
| title_sort | case of de novo neuroendocrine prostate cancer presented with elevated level of serum cea carrying brca2 mutation case report and literature review |
| topic | neuroendocrine prostate cancer (NEPC) carcinoembryonic antigen (CEA) homologous recombination repair (HRR) marker prostate cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1508410/full |
| work_keys_str_mv | AT weizhehan acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT nihatirexiati acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT fangyu acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT yongzhiwang acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT yuelitian acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT jianyuanwu acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT gangwang acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT taoliu acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT zhonghuayang acaseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT weizhehan caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT nihatirexiati caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT fangyu caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT yongzhiwang caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT yuelitian caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT jianyuanwu caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT gangwang caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT taoliu caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview AT zhonghuayang caseofdenovoneuroendocrineprostatecancerpresentedwithelevatedlevelofserumceacarryingbrca2mutationcasereportandliteraturereview |